SyntekaBio

SyntekaBio Earnings Yield

The Earnings Yield of SyntekaBio (226330.KQ) as of Nov 20, 2026 is -21.97 %. In the previous year, Earnings Yield was -9.12 % — a change of 140.92% (lower).

Earnings Yield

-21.97 %

YoY

140.92%

Last updated:

Earnings Yield of SyntekaBio is 2025 -21.97 % . Earnings Yield of SyntekaBio was 2024 -9.12 % . It decreases by 140.92% lower compared to the previous year.

The SyntekaBio Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2018
4.74 KRW
Jan 1, 2019
-29.04 KRW
Jan 1, 2020
-8.20 KRW
Jan 1, 2021
-18.72 KRW
Jan 1, 2022
-5.70 KRW
Jan 1, 2023
-14.41 KRW
Jan 1, 2024
-9.12 KRW
Jan 1, 2025
-21.97 KRW
The SyntekaBio Earnings Yield history
YEAREarnings YieldYoY
-21.97 %+140.92%
-9.12 %-36.71%
-14.41 %+152.92%
-5.70 %-69.56%
-18.72 %+128.16%
-8.20 %-71.75%
-29.04 %-712.99%
4.74 %-164.77%
-7.31 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

SyntekaBio Stock analysis

What does SyntekaBio do? SyntekaBio Inc. provides bioinformatics solutions through AI-driven software and services. The company develops and sells PMAP, a personal algorithm dielectric map platform using artificial intelligence, and offers clinical trial modeling and genome analysis services via big data. These services diagnose genetic diseases, select biomarker treatments, and predict disease risk. SyntekaBio also develops AI drug development technology and provides research services for candidate substances of immuno-cancer drugs. The primary customers for SyntekaBio's products include healthcare providers, research institutions, and pharmaceutical companies. Healthcare providers use the diagnostic and predictive services for patient care, while research institutions and pharmaceutical firms utilize the genome analysis and drug development technologies. The company's AI-driven tools are tailored to meet the needs of these segments, focusing on precision medicine and oncology applications. SyntekaBio's revenue streams come from software sales, service contracts for clinical trial modeling and genome analysis, and research services for immuno-cancer drug candidates. The company's AI drug development technology is a key offering, targeting pharmaceutical companies seeking to accelerate drug discovery and development processes. The firm's focus on AI and big data analytics positions it as a provider of specialized solutions in the bioinformatics sector. SyntekaBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about SyntekaBio stock

Earnings Yield of SyntekaBio is -21.97 % in 2025.

Earnings Yield of SyntekaBio changed from -9.12 % to -21.97 %, representing a 140.92% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield SyntekaBio since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's SyntekaBio with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — SyntekaBio

All Key Metrics — SyntekaBio